Selenium is an important component of the antioxidant enzyme, glutathione peroxidase (GSH-Px) that protects cells from the adverse effects of free radicals and lipid peroxides. A deficiency of selenium lowers the tissue activity of GSH-Px which in turn may have unfavorable effects on lipoprotein and arachidonic acid metabolism. These metabolic changes associated with compromised selenium status may lead to damage of the vascular endothelium and increased platelet adhesion which increase the risk of atherosclerotic heart disease.Since selenium mediates a number of insulin-like actions both in vivo and in vitro, this may be a potential mechanism for these actions.These data suggest that selenium may be beneficial in insulin resistance and potentially can modify the risk of diabetes and Ischemic Heart Disease (IHD) among patients with type 2 diabetes mellitus.The aim of this study is to evaluate the association between serum selenium and IHD among patients with type2 diabetes.20 type2 diabetic patients with Ischemic Heart Disease )IHD(, 20 type2 diabetic patients without Ischemic Heart Disease )IHD(, 10 healthy controls were studied.It was concluded that Serum selenium is not significantly lower in type 2 diabetic patients (ischemic and non ischemic) than healthy control and the association between serum selenium and IHD in diabetic patients is not significant.